Abstract 5374
Background
We aimed to validate the prognostic effects of the metastatic lymph nodes ratio (LNR) in patients with gastric neuroendocrine tumour (G-NET), and establish a nomogram to predict the survival of patients.
Methods
A total of 315 patients with G-NET in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 were included. Pearson correlation and Cox regression were performed to identify the association between LNR and survival. Nomograms were adopted to predict overall survival (OS) and cancer-specific survival (CSS).
Results
LNR has a negative correlation with OS and CSS (Pearson correlation coefficients: 0.343, P < 0.001; 0.389, P < 0.001, respectively). The multivariate analyses indicated age, tumour site, differentiation, T staging, M staging, chemotherapy and LNR were independent prognostic factors for both OS and CSS. The concordance index (C-index) of the nomograms for OS and CSS were superior to those of the TNM classification (0.773 vs. 0.731; 0.807 vs. 0.769, respectively). According to the area under the ROC curve (AUC), the predictive ability of the new nomogram for 3- and 5-year OS was better than TNM classification (0.908 vs. 0.846, P = 0.004; 0.899 vs. 0.827, P < 0.001, respectively). And the predictive ability of the new nomogram for 1-, 3- and 5-year CSS was better than TNM classification (0.936 vs. 0.848, P = 0.007; 0.910 vs. 0.855, P = 0.003; 0.894 vs. 0.836, P = 0.001, respectively).
Conclusions
LNR was an independent predictor of OS and CSS in G-NET. The nomograms based on the LNR were superior to the TNM classification in predicting the clinical outcomes for G-NET patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yaobin Lin.
Funding
The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract